accolade - ACCD
ACCD
Close Chg Chg %
3.71 -0.01 -0.27%
Closed Market
3.70
-0.01 (0.27%)
Volume: 1.34M
Last Updated:
Nov 22, 2024, 4:00 PM EDT
Company Overview: accolade - ACCD
ACCD Key Data
| Open $3.70 | Day Range 3.67 - 3.78 |
| 52 Week Range 3.08 - 15.36 | Market Cap $298.79M |
| Shares Outstanding 80.54M | Public Float 69.18M |
| Beta 2.02 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.03 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.32M |
ACCD Performance
| 1 Week | 6.63% | ||
| 1 Month | 15.99% | ||
| 3 Months | -16.29% | ||
| 1 Year | -54.49% | ||
| 5 Years | N/A |
ACCD Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
14
Full Ratings ➔
About accolade - ACCD
Accolade, Inc. engages in the provision of technology-enabled health and benefits solutions. The company was founded by Thomas K. Spann and J. Michael Cline in January 2007 and is headquartered in Seattle, WA.
ACCD At a Glance
Accolade, Inc.
1201 3rd Avenue
Seattle, Washington 98101
| Phone | 1-206-926-8100 | Revenue | 414.29M | |
| Industry | Information Technology Services | Net Income | -99,805,000.00 | |
| Sector | Technology Services | 2024 Sales Growth | 14.085% | |
| Fiscal Year-end | 02 / 2025 | Employees | 2,400 | |
| View SEC Filings |
ACCD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.853 |
| Price to Book Ratio | 1.796 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -12.263 |
| Enterprise Value to Sales | 1.864 |
| Total Debt to Enterprise Value | 0.313 |
ACCD Efficiency
| Revenue/Employee | 172,621.667 |
| Income Per Employee | -41,585.417 |
| Receivables Turnover | 14.955 |
| Total Asset Turnover | 0.49 |
ACCD Liquidity
| Current Ratio | 2.601 |
| Quick Ratio | 2.601 |
| Cash Ratio | 2.198 |
ACCD Profitability
| Gross Margin | 34.669 |
| Operating Margin | -27.418 |
| Pretax Margin | -23.792 |
| Net Margin | -24.09 |
| Return on Assets | -11.803 |
| Return on Equity | -21.714 |
| Return on Total Capital | -14.525 |
| Return on Invested Capital | -13.641 |
ACCD Capital Structure
| Total Debt to Total Equity | 54.246 |
| Total Debt to Total Capital | 35.169 |
| Total Debt to Total Assets | 30.66 |
| Long-Term Debt to Equity | 52.655 |
| Long-Term Debt to Total Capital | 34.137 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Accolade - ACCD
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 170.36M | 310.02M | 363.14M | 414.29M | |
Sales Growth
| +28.57% | +81.98% | +17.13% | +14.09% | |
Cost of Goods Sold (COGS) incl D&A
| 101.89M | 211.63M | 244.26M | 270.66M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 8.21M | 42.61M | 47.38M | 50.60M | |
Depreciation
| 6.76M | 6.02M | 4.89M | 7.37M | |
Amortization of Intangibles
| 1.45M | 36.59M | 41.49M | 37.80M | |
COGS Growth
| +23.95% | +107.71% | +15.42% | +10.81% | |
Gross Income
| 68.47M | 98.39M | 118.89M | 143.63M | |
Gross Income Growth
| +36.11% | +43.70% | +20.83% | +20.82% | |
Gross Profit Margin
| +40.19% | +31.74% | +32.74% | +34.67% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 115.25M | 256.32M | 274.41M | 257.22M | |
Research & Development
| 49.95M | 83.66M | 99.25M | 99.06M | |
Other SG&A
| 65.30M | 172.65M | 175.16M | 158.16M | |
SGA Growth
| +17.35% | +122.40% | +7.06% | -6.26% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | (32.20M) | 307.99M | (8.35M) | |
EBIT after Unusual Expense
| (46.78M) | (125.72M) | (463.51M) | (105.23M) | |
Non Operating Income/Expense
| (147.00K) | (133.00K) | 240.00K | 9.53M | |
Non-Operating Interest Income
| - | - | 255.00K | 8.82M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | 3.72M | 2.90M | 2.87M | |
Interest Expense Growth
| - | - | +27.32% | -21.99% | - |
Gross Interest Expense
| - | 3.72M | 2.90M | 2.87M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (50.65M) | (128.76M) | (463.27M) | (98.57M) | |
Pretax Income Growth
| +1.15% | -154.23% | -259.79% | +78.72% | |
Pretax Margin
| -29.73% | -41.53% | -127.57% | -23.79% | |
Income Tax
| 4.00K | (5.64M) | (3.62M) | 1.24M | |
Income Tax - Current - Domestic
| 37.00K | 200.00K | 246.00K | 1.05M | |
Income Tax - Current - Foreign
| 141.00K | 202.00K | 127.00K | 200.00K | |
Income Tax - Deferred - Domestic
| - | - | (5.99M) | (4.00M) | - |
Income Tax - Deferred - Foreign
| - | (174.00K) | (47.00K) | (13.00K) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (50.65M) | (123.12M) | (459.65M) | (99.81M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (50.65M) | (123.12M) | (459.65M) | (99.81M) | |
Net Income Growth
| +1.39% | -143.08% | -273.32% | +78.29% | |
Net Margin Growth
| -29.73% | -39.71% | -126.58% | -24.09% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (50.65M) | (123.12M) | (459.65M) | (99.81M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (50.65M) | (123.12M) | (459.65M) | (99.81M) | |
EPS (Basic)
| -1.7246 | -1.9291 | -6.4485 | -1.3324 | |
EPS (Basic) Growth
| -63.81% | -11.86% | -234.28% | +79.34% | |
Basic Shares Outstanding
| 29.37M | 63.82M | 71.28M | 74.91M | |
EPS (Diluted)
| -1.7246 | -1.9291 | -6.4485 | -1.3324 | |
EPS (Diluted) Growth
| -63.81% | -11.86% | -234.28% | +79.34% | |
Diluted Shares Outstanding
| 29.37M | 63.82M | 71.28M | 74.91M | |
EBITDA
| (38.56M) | (115.31M) | (108.15M) | (62.99M) | |
EBITDA Growth
| +2.09% | -199.01% | +6.22% | +41.76% | |
EBITDA Margin
| -22.64% | -37.20% | -29.78% | -15.20% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 7.432 | |
| Number of Ratings | 14 | Current Quarters Estimate | -0.33 | |
| FY Report Date | 11 / 2024 | Current Year's Estimate | -0.958 | |
| Last Quarter’s Earnings | -0.30 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.33 | Next Fiscal Year Estimate | -0.871 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 13 | 13 | 13 | 13 |
| Mean Estimate | -0.33 | 0.04 | -0.96 | -0.87 |
| High Estimates | -0.26 | 0.12 | -0.79 | -0.66 |
| Low Estimate | -0.44 | -0.05 | -1.34 | -1.50 |
| Coefficient of Variance | -14.37 | 133.78 | -13.89 | -25.17 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 9 | 11 | 12 |
| OVERWEIGHT | 1 | 1 | 0 |
| HOLD | 4 | 4 | 6 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Accolade - ACCD
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Accolade - ACCD
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Aug 20, 2024 | Michael W. Hilton Director | 148,885 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 20, 2024 | Michael W. Hilton Director | 3,317 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 20, 2024 | Robert N. Cavanaugh President | 193,812 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 20, 2024 | Robert N. Cavanaugh President | 193,659 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.14 per share | 801,748.26 |
| Aug 20, 2024 | Robert N. Cavanaugh President | 5,101 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 20, 2024 | Rajeev Singh Chief Executive Officer; Director | 785,138 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 20, 2024 | Rajeev Singh Chief Executive Officer; Director | 784,765 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.14 per share | 3,248,927.10 |
| Aug 20, 2024 | Rajeev Singh Chief Executive Officer; Director | 9,329 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 20, 2024 | Stephen H. Barnes Chief Financial Officer | 199,554 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 20, 2024 | Stephen H. Barnes Chief Financial Officer | 199,435 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.14 per share | 825,660.90 |
| Aug 20, 2024 | Stephen H. Barnes Chief Financial Officer | 4,147 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 9, 2024 | Cindy R. Kent Director | 35,021 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Aug 9, 2024 | Peter S. Klein Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 9, 2024 | Peter S. Klein Director | 35,021 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Aug 9, 2024 | Jeffrey D. Jordan Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 9, 2024 | Jeffrey D. Jordan Director | 35,021 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Aug 9, 2024 | Dawn G. Lepore Director | 35,021 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Aug 9, 2024 | Patricia L. Wadors Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 9, 2024 | Patricia L. Wadors Director | 35,021 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Aug 9, 2024 | Cindy R. Kent Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |